Skip to main content

Table 1 Approved immune checkpoint blockade therapies

From: Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine

Target Drug Company Cancer type Combination Genomic and other indications FDA approval date References
PD-1 Nivolumab Bristol-Meyers Squibb Company Inc. Metastatic small cell lung cancer   Progression after platinum-based chemotherapy and at least one other line of therapy August 16, 2018 [151]
   Metastatic colorectal cancer Ipilimumab Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) July 10, 2018 [152]
   Untreated advanced renal cell carcinoma Ipilimumab   April 16, 2018 [153]
   Melanoma Adjuvant treatment Involvement of lymph nodes December 20, 2017 [154]
   Hepatocellular carcinoma    September 22, 2017 [155]
   Metastatic colorectal cancer   Mismatch repair deficient (dMMR) and microsatellite instability-high (MSI-H) July 31, 2017 [156]
   Locally advanced or metastatic urothelial carcinoma    February 2, 2017 [157]
   Squamous cell carcinoma of the head and neck    November 10, 2016 [158]
   Classic Hodgkin lymphoma    May 17, 2016 [159]
   Advanced renal cell carcinoma    November 23, 2015 [160]
   Metastatic non-small cell lung cancer    October 9, 2015 [161]
   Metastatic melanoma Ipilimumab BRAF V600 wild type September 30, 2015 [162]
   Metastatic squamous non-small cell lung cancer    March 4, 2015 [163]
   Unresectable or metastatic melanoma    December 22, 2014 [164]
Pembrolizumab Merck & Co, Inc. Non-small cell lung cancer Carboplatin and either paclitaxel or nab-paclitaxel   October 30, 2018 [165]
   Metastatic, non-squamous non-small cell lung cancer Pemetrexed and platinum   August 20, 2018 [166]
   Primary mediastinal large B cell lymphoma    June 13, 2018 [167]
   Metastatic cervical cancer   Express PD-L1 (combined positive score ≥ 1) June 12, 2018 [168]
   Gastric or gastroesophageal junction adenocarcinoma   Express PD-L1 September 22, 2017 [169]
   Solid tumors   Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) May 23, 2017 [170]
   Urothelial carcinoma    May 18, 2017 [171]
   Metastatic non-squamous non-small cell lung cancer Pemetrexed and carboplatin   May 10, 2017 [172]
   Classic Hodgkin lymphoma    March 14, 2017 [173]
   Metastatic non-small cell lung cancer   Express PD-L1 October 24, 2016 [174]
   Recurrent or metastatic head and neck squamous cell carcinoma    August 5, 2016 [175]
   Unresectable or metastatic melanoma    December 18, 2015 [176]
   Metastatic non-small cell lung cancer   Express PD-L1 October 2, 2015 [177]
   Unresectable or metastatic melanoma   Following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor September 4, 2014 [178]
PD-L1 Atezolizumab Genentech Oncology Metastatic non-small cell lung cancer    October 18, 2016 [179]
   Locally advanced or metastatic urothelial carcinoma    May 18, 2016 [180]
Durvalumab AstraZeneca Inc. Stage III non-small cell lung cancer    February 16, 2018 [181]
   Locally advanced or metastatic urothelial carcinoma    May 1, 2017 [182]
Avelumab EMD Serono, Inc. Metastatic Merkel cell carcinoma    March 23, 2017 [183]
CTLA-4 Ipilimumab Bristol-Meyers Squibb Company, Inc. Metastatic colorectal cancer Nivolumab Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) July 10, 2018 [152]
   Untreated advanced renal cell carcinoma Nivolumab   April 16, 2018 [153]
   Cutaneous melanoma    October 28, 2015 [184]
   BRAF V600 wild-type, unresectable or metastatic melanoma Nivolumab   September 30, 2015 [162]